ALKS 7106

Drug Profile

ALKS 7106

Alternative Names: ALKS7106

Latest Information Update: 28 Feb 2015

Price : $50

At a glance

  • Originator Alkermes plc
  • Class Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 24 Feb 2015 Discontinued - Phase-I for Pain (In volunteers) in USA (PO)
  • 26 Aug 2014 Phase-I clinical trials in Pain (In volunteers) in USA (PO)
  • 17 Jul 2013 Preclinical trials in Pain in Ireland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top